** Shares in Ion Beam Applications IBAB.BR fall nearly 10%, reversing course after rising around 4% in early trading, after the Belgian radiation therapy and radiopharmaceuticals equipment co announced a prudent 2025, mid-term guidance despite FY beat
** ING says 2025 REBIT guidance is on the "low side" and 2026 outlook "dropped"
** Co updated mid-term outlook, now sees 2024-28 revenue CAGR of 5-7%, c.10% REBIT margin by 2028; 2025 REBIT of at least 25 million euros ($27.13 million)
** "Management is more prudent on timing based on volatile order intake and current macro-economic context, which is in our view not reassuring," Degroof Petercam adds, 2025 REBIT guidance coming below its expectations
** ING fears higher short-term uncertainty may outweigh the reassuring long-term shift from the volatile PT case to lower-risk, higher-margin industrial/radio pharma accelerators
** "Management might simply play it safe here," the broker adds
** Shares are on track for their worst day in nearly nine months
($1 = 0.9216 euros)
(Reporting by Olivier Cherfan)
((olivier.cherfan@thomsonreuters.com))